Friday, 06 Dec 2019

You are here

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

While it is well known that TNFi do not confer any higher or additional risk of neoplasia in adults treated for rheumatoid arthritis and other inflammatory conditions, the issue is less clear in children. Current product labeling states "..lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers..", based on the best available data (albeit limited) from registries and spontaneous postmarketing reports. 

What has been lacking is clear understanding of the background cancer risk in polyarticular JIA along with well-designed trials to examine if there is an additional risk imposed by the biologic drug.

This retrospective cohort study examined pediatric patients with juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO), exposed to their first TNFi. Standardised incidence ratios (SIRs) comparing the observed number of malignancies to the expected numbers according to cancer surveillance data.  

Among 15,598 children treated with TNFi and 73 839 children without TNFi exposure, they found 15 malignancies among children with TNFi use (SIR 2.9 (1.6 to 4.9)) and 42 malignancies among children without TNFi use (SIR 2.1 (1.5 to 2.9)).

The adjusted hazard ratio (aHR) was 1.58 (0.88 to 2.85) for TNFi use versus no TNFi use.

In pIBD, thiopurine plus TNFi use was associated with a higher SIR (aHR 6.0 (1.2 to 17.5)) compared with TNFi use without thiopurine use (2.5 (0.7 to 6.4)).

Children diagnosed with JIA, pIBD and pPsO had an increased rate of malignancy compared with the general population.

However, TNFi did not appear to significantly further increase the risk compared with no TNFi use. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.

Adalimumab and Pregnancy Outcomes

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increased risk for any of the adverse outcomes examined.

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).